Biovitrum AB (publ) announces terms of the rights issue

Read the whole press release at:
http://www.biovitrum.com/templates/InformationPage.aspx?id=818


For further information, please contact:

Biovitrum AB (publ)
Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Göran Arvidson, CFO
Phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. Biovitrum has revenues of approximately SEK 1.2
billion and approximately 400 employees (prior to the Transaction).
Biovitrum's head office is located in Sweden and the share is listed
on the NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com.

The above information has been made public in accordance with the
Securities Market Act and/or the Financial Instruments Trading Act.
The information was published at 8:00 CET on December 2nd, 2009.